IDWeek 2017

Thirteen of AWG’s member companies presented data from their clinical and research programs at IDWeek 2017. In addition to 59 poster presentations, representatives from AWG member companies participated in various panels and symposiums addressing the current state of the antimicrobial development pipeline.

IDWeek is an annual scientific meeting that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.

AWG Member Company Participation at IDWeek 2017

Wednesday, October 4th

Affiliated Event
Time: 7:00 AM – 8:00 AM
Room: 09

T2Sepsis Solution: The Impact of Direct from Whole Blood Diagnostics on the Management of Bloodstream Infections (T2Candida and the T2Bacteria RUO Panel)

  • T2 Biosystems

Thursday, October 5th

Poster Abstract Session
Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD

HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens
Iterum Therapeutics:

Emerging Resistance – Epidemiology and Mechanisms
Melinta Therapeutics:

Theravance Biopharma:

Clinical: Bone and Joint Infection
Theravance Biopharma:

Fungus Among Us: Basic Science
Viamet Pharmaceuticals:

Thursday, October 5th

Symposium
Time: 2:00 PM – 3:00 PM
Room: 20ABCD

New Antibiotics: What’s in the Pipeline

Melinta Therapeutics:
Time:  2:00 PM 

Zavante Therapeutics:
Time: 2:09 PM

Paratek Pharmaceuticals:
Time: 2:36 PM

Nabriva Therapeutics:
Time: 2:45 PM

 

Friday, October 6th

Meet the Professor Session
Time: 7:00 AM – 8:15 AM
Room: 06DE

Pipeline 2.0 

AWG Panelists:

  • Sue K. Cammarata, MD – Melinta Therapeutics
  • Evelyn J. Ellis-Grosse, Ph.D. – Zavante Therapeutics, Inc.
  • Paul McGovern, MD – Paratek Pharmaceuticals
  • Steven P. Gelone, PharmD – Nabriva Therapeutics AG


Poster Abstract Session

Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD

Adult Immunization – Miscellaneous
Arsanis:

Preclinical Study with New Antibiotics and Antifungals
Amplyx Pharmaceuticals:

Cidara Therapeutics:

Melinta Therapeutics:

Nabriva Therapeutics:

Paratek Pharmaceuticals:

Scynexis:

Zavante Therapeutics:

Expanded Spectrum – New Antimicrobial Susceptibility Testing
Contrafect Corporation:

Melinta Therapeutics:

Nabriva Therapeutics:

Paratek Pharmaceuticals:

Scynexis:

Zavante Therapeutics:

Saturday, October 7th

Oral Abstract Session
Time: 8:30 AM – 10:00 AM
Room: 01AB

The Fungus Among-us – Clinical Advances
T2 Biosystems:

Poster Abstract Session
Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD

Clinical Study with New Antibiotics and Antifungals
Arsanis:

Amplyx Pharmaceuticals:

Iterum Therapeutics:

Melinta Therapeutics:

Paratek Pharmaceuticals:

Theravance Biopharma:

Zavante Therapeutics:

Diagnostics – Mycology
T2 Biosystems:

Stewardship: Impact of Diagnostics
T2 Biosystems: